tbuckley/cabot-search huggingface dataset:
Abstract 20061: Towards Predicting the Rate and Rhythm of Rearrest After Out-of-hospital Cardiac Arrest
Authors: David Salcido, Matthew L Sundermann, Allison C Koller, James J Menegazzi
Journal: Circulation (2015)

Background/Aims: Rearrest (RA) after resuscitation from out-of-hospital cardiac arrest (OHCA) has been shown to be an independent predictor of death before hospital discharge. The aim of this study was to understand how heart rate and rhythm transitions relate to the timing and presentation of rearrest. Methods: Case data for emergency medical services (EMS)-treated OHCA were obtained from the Resuscitation Outcomes Consortium (ROC) for the period 2006-2008. Cases with analyzable electrocardiogram (ECG) signals were included in the study. RA events were ascertained by an inferential scheme involving the presence of a life-threatening ECG rhythm and/or presence of chest compressions. ROSC-RA ECG intervals were extracted from defibrillator source files and imported into custom software for calculation of several heart rate characteristics for 30s, 1min, 3min, and 5min epochs beginning at the onset of ROSC, including: mean heart rate, standard deviation for heart rate (SD-HR), root mean square of the successive differences (RMSSD), and approximate entropy of heart rate (ApEn). Frequency-based heart rate variability measures including normalized high frequency power (HFN), normalized low frequency power (LFN), and ratio of low and high frequency power (LFHF) were calculated. Multivariable generalized estimating equations (GEE) were used to assess the relationship between heart rate characteristics and time-to-RA while controlling for RA event number, presenting OHCA ECG rhythm, and RA ECG rhythm. Rhythm transitions were assessed and compared with Fisher’s exact test. Results: In univariate analyses RMSSD in the 30s and 1-minute epoch epochs, SD-HR in the 5-minute epoch, ApEn in the 5-minute epoch, presenting ECG rhythm ventricular fibrillation / ventricular tachycardia (VF/VT), and RA event number were predictive of time-to-RA. In a multivariable model, only SD-HR in the 5-minute epoch was related to time-to-RA (coeff. = -764.16; 95%CI: -1405.92 , -122.40; p = 0.020). The most common first rhythm transition was from VF/VT to VF/VT. Conclusions: At least one heart rate-derived measure, SD-HR, was related to time-to-RA event, independent of RA ECG rhythm, presenting OHCA ECG rhythm or RA event number.
Potential Benefits of Computer-Aided Detection for Cancer Identification and Treatment
Authors: Rachel Brem
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Healing the Bee’s Knees—On Honey and Wound Healing
Authors: Tetyana Rogalska
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Postoperative FGF-23 levels are associated with AKI
Authors: Ellen F. Carney
Journal: Nature Reviews Nephrology (2016)

Postoperative FGF-23 levels are associated with AKILevels of FGF-23 increase early in the course of acute kidney injury (AKI) following cardiac surgery and are independently associated with severe AKI and adverse outcomes, say researchers.Among 250 patients undergoing cardiac surgery, those who developed AKI had significantly higher levels of plasma c-terminal FGF-23 at the end of cardiopulmonary bypass and on postoperative days 1 and 3.In those who developed severe AKI, the levels of intact FGF-23 also increased after surgery.
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B …
Authors: Nicolaos C. Tassopoulos, Riccardo Volpes, Giuseppe Pastore, Jenny Heathcote, Maria Buti, Robert D. Goldin, Sasha Hawley, Judy Barber, Lynn Condreay, Fraser D. Gray
Journal: Hepatology (1999)

This placebo controlled, double–blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)–negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n = 60) or placebo for 26 weeks (n = 65). Patients who were HBV DNA positive at week 24 were withdrawn at week 26. The primary efficacy endpoint was loss of serum HBV DNA plus normalization of alanine transaminase (ALT) at week 24. A significantly higher proportion of patients receiving lamivudine (63%) had a complete response at week 24 compared with patients receiving placebo (6%) ( P &lt; .001). Secondary efficacy parameters included histological response from baseline to week 52 in the lamivudine–treated patients. At week 52, 60% of lamivudine–treated patients with liver biopsy specimens available showed histological improvement (≥2–point reduction in Knodell necro–inflammatory score), 29% showed no change, and 12% worsened. In a ranked assessment of pretreatment and post–treatment biopsy pairs 11% improved, 86% showed no change, and 2% worsened in fibrosis. At week 52, 27% of patients receiving lamivudine had YMDD (tyrosine–methionine–aspartate–aspartate amino acid motif of HBV polymerase) variant HBV. The incidence of adverse events and laboratory abnormalities was similar in both groups. In conclusion, lamivudine treatment results in a significant virological and biochemical improvement compared with placebo, induces an improvement or no change in histology in most patients, and is well tolerated. The response to lamivudine therapy in HBeAg–negative patients is similar to the response reported in previous studies of patients with HBeAg–positive chronic hepatitis B.
Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts: Interim Report of a Prospective Comparative Trial
Authors: Alberto S. Tagliafico, Massimo Calabrese, Giovanna Mariscotti, Manuela Durando, Simona Tosto, Francesco Monetti, Sonia Airaldi, Bianca Bignotti, Jacopo Nori, Antonella Bagni, Alessio Signori, Maria Pia Sormani, Nehmat Houssami
Journal: Journal of Clinical Oncology (2016)

Debate on adjunct screening in women with dense breasts has followed legislation requiring that women be informed about their mammographic density and related adjunct imaging. Ultrasound or tomosynthesis can detect breast cancer (BC) in mammography-negative dense breasts, but these modalities have not been directly compared in prospective trials. We conducted a trial of adjunct screening to compare, within the same participants, incremental BC detection by tomosynthesis and ultrasound in mammography-negative dense breasts.Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts is a prospective multicenter study recruiting asymptomatic women with mammography-negative screens and dense breasts. Eligible women had tomosynthesis and physician-performed ultrasound with independent interpretation of adjunct imaging. Outcome measures included cancer detection rate (CDR), number of false-positive (FP) recalls, and incremental CDR for each modality; these were compared using McNemar's test for paired binary data in a preplanned interim analysis.Among 3,231 mammography-negative screening participants (median age, 51 years; interquartile range, 44 to 78 years) with dense breasts, 24 additional BCs were detected (23 invasive): 13 tomosynthesis-detected BCs (incremental CDR, 4.0 per 1,000 screens; 95% CI, 1.8 to 6.2) versus 23 ultrasound-detected BCs (incremental CDR, 7.1 per 1,000 screens; 95% CI, 4.2 to 10.0), P = .006. Incremental FP recall occurred in 107 participants (3.33%; 95% CI, 2.72% to 3.96%). FP recall (any testing) did not differ between tomosynthesis (FP = 53) and ultrasound (FP = 65), P = .26; FP recall (biopsy) also did not differ between tomosynthesis (FP = 22) and ultrasound (FP = 24), P = .86.The Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts' interim analysis shows that ultrasound has better incremental BC detection than tomosynthesis in mammography-negative dense breasts at a similar FP-recall rate. However, future application of adjunct screening should consider that tomosynthesis detected more than 50% of the additional BCs in these women and could potentially be the primary screening modality.
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
Authors: Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher
Journal: Journal of Hematology & Oncology (2016)

ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study ( NCT01284192 ) assessed the safety, pharmacokinetic profile, and antitumor activity of ASP3026. Advanced solid tumor patients received oral ASP3026 in 3 + 3 dose-escalation cohorts at doses of 25–800 mg once daily in 28-day cycles. The endpoints were to identify the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the pharmacokinetic profile of ASP3026. A phase Ib expansion cohort enrolled patients with metastatic, crizotinib-resistant ALK-positive solid tumors at the RP2D, and response was evaluated by RECIST 1.1. The dose-escalation cohort enrolled 33 patients, including three crizotinib-resistant, ALK-positive patients, and the dose-expansion cohort enrolled another 13 crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC) patients. ASP3026 demonstrated both linear pharmacokinetics and dose-proportional exposure for area under the plasma concentration–time curve and maximum concentration observed with a median terminal half-life of 35 h, supporting the daily dosing. Grade 3 rash and elevated transaminase concentrations were dose-limiting toxicities observed at 800 mg; hence, 525 mg daily was the MTD and RP2D. The most common treatment-related adverse events were nausea (38 %), fatigue (35 %), and vomiting (35 %). Among the 16 patients with crizotinib-resistant ALK-positive tumors (15 NSCLC, 1 neuroblastoma), eight patients achieved partial response (overall response rate 50 %; 95 % confidence interval 25–75 %) and seven patients (44 %) achieved stable disease. ASP3026 was well tolerated and had therapeutic activity in patients with crizotinib-resistant ALK-positive advanced tumors. ClinTrials.gov: NCT01284192
A Practical Treatise on Diseases of the Skin for the Use of Students and Practitioners.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Prescreening Device for Cancer of the Uterus
Authors: Ruth M. Graham, Michael M. Graham
Journal: JNCI Journal of the National Cancer Institute (1976)

A prescreening device for cancer of the uterus was based on the slower sedimentation rate of cells from a vaginal aspirate in the presence of cancer than in its absence. The apparatus recorded the increase in light transmission through the test tube as the cells fell. This mechanical examination of the rate of fall of vaginal and cervical cells did not diagnose cancer, but it identified the normal specimens free of cancer or infections. The negative specimens comprised the bulk of diagnostic material. There was a small increase in false-negative rate compared with the false-negative rate in standard cytologic tests, but this was counterbalanced by the increase in the number of specimens examined.
A Case of "Disease of the Intercalated Disc" Demonstrated in Obstructive Cardiomyopathy
Authors: Shigetaka Sasayama, Shinichiro Kubo, Makoto Watanabe, Reizo Kusukawa
Journal: Circulation (1971)

A cace of obstructive cardiomyopathy has been presented. A pressure gradient was evident across the outflow tract of both ventricles under resting condition. Angiocardiography showed marked hypertrophy of the interventricular septum which bulged into the right ventricle as well as into the left. Ventriculo-myotomy was carried out to relieve the obstruction. Special attention was directed to the ultrastructural findings of the resected myocardium, which showed dissociation of the intercalated  The condition offers addition-al support to the concept of disease of the intercalated disc.
Chromosome Abnormalities as Primary Events in Human Malignant Disease: Evidence From Marker Chromosomes&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: N. B. Atkin, Marion C. Baker
Journal: JNCI Journal of the National Cancer Institute (1966)

Observations on the chromosomes of cells from 5 human malignant tumors are reported. Each tumor had one or more distinctive marker chromosomes. Marker chromosomes were present in a total of 700 of 711 metaphases from these tumors, which included an early malignant lesion of the cervix showing minimal invasion. Two tumors (a Stage 4 carcinoma of the cervix and a reticulum cell sarcoma, both untreated) yielded preparations of high quality. The 7 best-spread metaphases from the former with the modal number of chromosomes (60) had identical karyotypes, as did 16 from the latter with the modal number of 49. Less extensive data on 13 other tumors, 8 of which had marker chromosomes, are also presented. The data presented here, together with the published data on the chromosomes of cells from human tumors, support the view that human malignant tumors frequently but not invariably arise from a single cell in which chromosome changes have occurred. A carcinoma of the corpus uteri, to which brief reference is made, is a possible exception: Most metaphases had apparently normal karyotypes. The role of chromosome abnormalities (particularly structural changes) in the malignant transformation is discussed. Possible parallels between the chromosome findings in the cells of malignant tumors and those in chronic myeloid leukemia are considered. It is suggested that in tumors there may be both specific changes (perhaps involving chromosomes structurally changed) and coincidental changes. Variation in the coincidental changes might largely account for the wide differences between the karyotypes of different tumors.
A comparison of delinquent and nondelinquent adolescent psychiatric inpatients
Authors: S S Shanok, S C Malani, O P Ninan, P Guggenheim, H Weinstein, D O Lewis
Journal: American Journal of Psychiatry (1983)

The psychopathology of 29 delinquent and 25 nondelinquent psychiatrically hospitalized adolescent boys was similarly severe. Similar proportions had hallucinations, delusions, learning disabilities, and evidence of neurological impairment, and over half in each group had been diagnosed as being psychotic. Fire-setting, enuresis, and cruelty to animals did not distinguish the two groups. Significantly more of the delinquents had been psychiatrically hospitalized previously, and significantly more of the delinquents had engaged in violently aggressive acts. The household composition of both groups was similar, but more mothers of delinquents than of nondelinquents had been psychiatrically hospitalized. The authors discuss the issue of the treatment of psychiatrically ill violent adolescents.
The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors
Authors: Sule Ozturk Sari, Orhun Cig Taskin, Gokcen Gundogdu, Gulcin Yegen, Semen Onder, Metin Keskin, Sezer Saglam, Yasemin Ozluk, Mine Gulluoglu, Ozgur Mete
Journal: Endocrine Pathology (2016)
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ—Reply
Authors: Steven A. Narod
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Haploidentical Hematopoietic Stem Cell Transplantation: A New Transplantation Modality Implemented In a Recent Accredited FACT Institution In Latin America
Authors: Fabio Ps Santos, Morgani Rodrigues, Jairo Jose, Nascimento Sobrinho, Ricardo Helman, Guilherme Fleury Perini, Reijane Alves de Assis, Andreza Alice Feitosa Ribeiro, Jose Mauro Kutner, Araci M. Sakashita, Margareth Torres, Physician, Leonardo Raul Morelli, Claudia Mac-Donald Bley do Nascimento, Alessandro de Moura Almeida, Joyce Esteves Hippolito, Andrea Tiemi Kondo, Juliana Folloni Fernandes, Fabio Rodrigues Kerbauy, Nelson Hamerschlak
Journal: Blood (2013)
Health care professionals' attitudes, perceptions, and practices regarding breast self-examination.
Authors: Kah Poh Loh, Eng Keong Tan, Jennifer Friderici, Reva Kleppel, Mihaela Stefan, Owolabi Ogunneye, James A Stewart
Journal: Journal of Clinical Oncology (2014)

e12513 Background: In 2009, the United States Preventive Service Task Force (USPSTF) published a revised guideline for breast cancer screening. The objectives of this study is to assess healthcare professionals' knowledge, perception and attitude in BSE as well as their adherence to the newly revised USPSTF guideline in BSE. Methods: A cross-sectional survey study was carried out in 5 medical and gynecogical practices affiliated with a large academic teaching hospital in Western Massachusetts. The survey was populated and e-mailed to all attendings, residents, advanced practitioners (APs), physician assistants (PAs) and nurses working in these medical practices. The survey contains demographic data and enquires their awareness and perceptions of the 2009 USPSTF guidelines in BSE followed by their practices in BSE. Results: The survey completion rate was 50.7% (104/205). Fewer than half of respondents correctly perceived the 2009 USPSTF guidelines for BSE (41.4%, 95% CI 31.7%, 51.0%). Most (70.2%, 95% CI 61.3%, 79.1%) teach patients to perform BSE. The most frequent reason cited for teaching BSE was